

# AutoImmune Incorporated

[View the current AutoImmune Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporcorporate/413-AutoImmune+Incorporated.html)

(<http://www.bioportfolio.com/bioporcorporate/413-AutoImmune+Incorporated.html>)

## Contact Details:

**1199 Madia Street**  
**Pasadena**  
**CA**  
**91103**  
**United States of America**

Tel: 626 792 1235  
Fax: 626 792 1236  
Email:

AutoImmune Inc. is a biopharmaceutical company developing a new class of orally administered pharmaceutical products for the treatment of autoimmune and other cell-mediated inflammatory diseases and conditions. At the start of 1999 the Company was conducting clinical trials for the following products: Colloral(R), for the treatment of rheumatoid arthritis, and AI 502, for the treatment of chronic transplant rejection. A third product, AI 401, for the treatment of Type 1 diabetes, is in Phase II clinical trials supported by Eli Lilly and Company ("Lilly") and the National Institutes of Health ("NIH"). The Company believes, based on preclinical and clinical data, that its proprietary approach to therapy can induce tissue-specific immunosuppression without toxicity or significant side effects. Additional clinical and commercial advantages of this approach include the ability to administer products orally (the preferred method of treating chronic diseases) and the potential for application to a variety of inflammatory diseases and conditions.

## Recent Publications by AutoImmune Incorporated:



- [HLA-class I markers and multiple sclerosis susceptibility in the Italian population.](#)  
*Previous studies reported an association with multiple sclerosis (MS) of...*13th November, 2009  
Department of Medical Sciences and Interdisciplinary Research Center of- Genes Immun. 2009 Nov 12. ([DOI Direct Link](#))
- [A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis.](#)  
*In primary biliary cirrhosis (PBC) serum markers other than...*10th November, 2009  
Center for Autoimmune Diseases Sheba Medical Center, Israel; Department of- J Autoimmun. 2009 Nov 6. ([DOI Direct Link](#))
- [HLA class II polymorphism in Latin American patients with multiple sclerosis.](#)  
*OBJECTIVE: To identify HLA-DRB1 alleles contributing to susceptibility to...*10th November, 2009  
Center for Autoimmune Diseases Research (CREA), School of Medicine and- Autoimmun Rev. 2009

- Nov 4. ([DOI Direct Link](#))
- [Inflammatory bowel disease: adverse effect of isotretinoin.](#)  
*OBJECTIVE: To identify HLA-DRB1 alleles contributing to susceptibility to...*7th November, 2009  
 Center for Autoimmune Diseases, Sheba Medical Center Tel-Hashomer and- Isr Med Assoc J. 2009  
 Aug;11(8):505-6.
  - [CsA exposure is associated with acute GVHD and relapse in children after SCT.](#)  
*CsA is commonly used after haematological SCT (HSCT) as GVHD prophylaxis....*3rd November, 2009  
 Department of Paediatrics, Division of Immunology, Haematology, Oncology- Bone Marrow Transplant.  
 2009 Nov 2. ([DOI Direct Link](#))
  - [Adjuvants and autoimmunity.](#)  
*Some adjuvants may exert adverse effects upon injection or, on the other...*3rd November, 2009  
 Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer,- Lupus. 2009  
 Nov;18(13):1217-25. ([DOI Direct Link](#))
  - [Transverse myelitis and vaccines: a multi-analysis.](#)  
*Transverse myelitis is a rare clinical syndrome in which an...*3rd November, 2009  
 Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer,- Lupus. 2009  
 Nov;18(13):1198-204. ([DOI Direct Link](#))
  - [Ten cases of systemic lupus erythematosus related to hepatitis B vaccine.](#)  
*The objective of this article is to identify common and atypical features...*3rd November, 2009  
 Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer,- Lupus. 2009  
 Nov;18(13):1192-7. ([DOI Direct Link](#))
  - [Molecular mimicry in systemic lupus erythematosus.](#)  
*Systemic lupus erythematosus is a multi-systemic autoimmune disease...*3rd November, 2009  
 Department of Medicine B, and The Center for Autoimmune Diseases Sheba- Lupus. 2009  
 Nov;18(13):1181-5. ([DOI Direct Link](#))
  - [Common infectious agents prevalence in antiphospholipid syndrome.](#)  
*Antiphospholipid syndrome is characterized by thrombosis and pregnancy...*3rd November, 2009  
 Department of Medicine B and Center of Autoimmune Diseases, Sheba Medical- Lupus. 2009  
 Nov;18(13):1149-53. ([DOI Direct Link](#))
  - [Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus.](#)  
*Environmental factors are capable of triggering the expression of human...*3rd November, 2009  
 Center for Autoimmune Diseases, an Department of Medicine B, Sheba Medical- Lupus. 2009  
 Nov;18(13):1136-43. ([DOI Direct Link](#))
  - [Etiopathogenesis of Behcet's disease.](#)  
*Behcet's disease (BD) is an inflammatory, multi systemic disease with...*3rd November, 2009  
 Systemic Autoimmune Diseases Research Unit, HGR #36, Instituto Mexicano- Autoimmun Rev. 2009  
 Oct 30. ([DOI Direct Link](#))
  - [Toward the early diagnosis of systemic sclerosis: warning signs the practitioner needs to recognize.](#)  
*Systemic sclerosis, or scleroderma, is a rare condition that first...*3rd November, 2009  
 Division of Rheumatic and Autoimmune Diseases, University of Minnesota,- Minn Med. 2009  
 Sep;92(9):42-4.
  - [The 423Q polymorphism of the X-linked inhibitor of apoptosis gene influences monocyte function and is associated with periodic fever.](#)  
*OBJECTIVE: Hereditary periodic fever syndromes (HPFs) develop as a result...*31st October, 2009  
 Interdisciplinary Research Centre of Autoimmune Diseases, and University- Arthritis Rheum. 2009  
 Nov;60(11):3476-84. ([DOI Direct Link](#))
  - [Vaccines and autoimmunity.](#)  
*Vaccines have been used for over 200 years and are the most effective way...*30th October, 2009  
 Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical- Nat Rev Rheumatol.  
 2009 Nov;5(11):648-52. ([DOI Direct Link](#))

## Press Releases on AutoImmune Incorporated:

<a href="#">H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics</a>	20th November, 2009	Quest Diagnostics Incorporated	<i>-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during</i>
<a href="#">New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)</a>	20th November, 2009	Quest Diagnostics Incorporated	<i>MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,</i>
<a href="#">Spherix Announces the Closing of \$6.3 Million Registered Direct Offering</a>	19th November, 2009	Spherix Incorporated	<i>BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting</i>
<a href="#">Spherix Announces Results of Annual Shareholders Meeting</a>	19th November, 2009	Spherix Incorporated	<i>-- Robert J. Vander Zanden, Ph.D., former Vice President, R&amp;D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants</i>
<a href="#">Give Your Pooch the Gift of Wisdom This Holiday</a>	19th November, 2009	Mars Veterinary	<i>ROCKVILLE, Md., Nov. 19 /PRNewswire/ -- There is no greater love than the adoration you receive from man's best friend. This holiday season, return the love by gifting your four legged friend</i>

## BioNews Results for AutoImmune Incorporated



- [Record Number of New Medicines in Development for Women](#)  
*Pharma Live: Nov 15 2009 7:05PM Matching: autoimmune*
- [New market research report on inflammation drugs](#)  
*News-Medical.Net: Nov 13 2009 2:29PM Matching: autoimmune*

- [Chemokine-Like Receptor-1 Expression by Central Nervous System-Infiltrating Leukocytes and Involvement in a Model of Autoimmune Demyelinating Disease](#)  
*MDLinx: Nov 13 2009 11:04AM Matching: autoimmune*
- [Reportlinker Adds Autoimmune and Inflammation Inflammation](#)  
*Montana's News Station: Nov 12 2009 7:30PM Matching: autoimmune*
- [Reportlinker Adds Autoimmune and Inflammation Inflammation](#)  
*KSLA: Nov 12 2009 8:41PM Matching: autoimmune*
- [IVAX Diagnostics, Inc. Reports Third Quarter 2009 Financial Results](#)  
*Yahoo! Canada: Nov 12 2009 9:39PM Matching: autoimmune*
- [Record Number of New Medicines in Development for Women](#)  
*KSLA: Nov 12 2009 3:33PM Matching: autoimmune*
- [AutoImmune Inc. Reports 2009 Third Quarter Financial Results](#)  
*Genetic Engineering News: Nov 11 2009 3:48PM Matching: autoimmune*
- [AutoImmune Inc. Reports 2009 Third Quarter Financial Results](#)  
*Montana's News Station: Nov 11 2009 3:23PM Matching: autoimmune*
- [AutoImmune Inc. Reports 2009 Third Quarter Financial Results](#)  
*KOTA Territory News: Nov 11 2009 1:04PM Matching: autoimmune*
- [AutoImmune Inc. Reports 2009 Third Quarter Financial Results](#)  
*SmartBrief: Nov 11 2009 10:20AM Matching: autoimmune*
- [AutoImmune Inc. Reports 2009 Third Quarter Financial Results](#)  
*NewsBlaze: Nov 11 2009 12:13AM Matching: autoimmune*
- [AutoImmune Inc. Reports 2009 Third Quarter Financial Results](#)  
*Freshnews.com: Nov 11 2009 1:49AM Matching: autoimmune*
- [Autoimmune Hepatitis and Liver Transplantation: Indications, Results, and Management of Recurrent Disease](#)  
*Seminars In Liver Disease: Nov 11 2009 10:35AM Matching: autoimmune*
- [Clinical, Immunological, and Genetic Features of Autoimmune Primary Adrenal Insufficiency: Observations from a Norwegian Registry](#)  
*MDLinx: Nov 11 2009 10:13AM Matching: autoimmune*

#### AutoImmune Incorporated Patents:



- 6703361- [Method of treating or preventing Type 1 diabetes by oral administration of insulin](#)
- 5807993- [HP-8 autoantigen](#)
- 5788968- [Methods and compositions for suppressing allograft rejection in mammals](#)
- 5783188- [Method of treating rheumatoid arthritis with type collagen peptide fragments containing repeating sequences](#)
- 5763396- [Method of treating or preventing type 1 diabetes by oral administration of insulin](#)
- 5733547- [Treatment of autoimmune arthritis by oral administration of type I or type III collagen](#)
- 5720955- [Method of treating rheumatoid arthritis with soluble collagen](#)
- 5681556- [Method and compositions for suppressing allograft rejection in mammals](#)
- 5645820- [Treatment of autoimmune diseases by aerosol administration of autoantigens](#)
- 5643868- [Method of treating or preventing type 1 diabetes by oral administration of insulin](#)
- 5641474- [Prevention of autoimmune diseases by aerosol administration of autoantigens](#)

- 5641473- [Treatment of autoimmune diseases by aerosol administration of autoantigens](#)
- 5593698- [Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides](#)
- 5571500- [Treatment of autoimmune diseases through administration by inhalation of autoantigens](#)
- 5571499- [Treatment of autoimmune diseases by aerosol administration of autoantigens](#)
- 5840848- [Method for preparation of type II collagen](#)
- 5843445- [Method of treating rheumatoid arthritis with type II collagen](#)
- 5843886- [Method of treating or preventing Type 1 diabetes by oral administration of insulin](#)
- 6645504- [Bystander suppression of type I diabetes by oral administration of glucagon](#)
- 6077509- [Peptide fragments of myelin basic protein](#)
- 6039947- [Peptides derived from immunodominant epitopes of myelin basic protein](#)
- 6036957- [Suppression of T-cell proliferation using peptide fragments of myelin basic protein](#)
- 6019971- [Treatment of autoimmune arthritis by oral administration of collagen](#)
- 5961977- [Method of treating or preventing autoimmune uveoretinitis in mammals](#)
- 5935577- [Treatment of autoimmune disease using tolerization in combination with methotrexate](#)
- 5869093- [Treatment of immune diseases by oral administration of autoantigens](#)
- 5869054- [Treatment of multiple sclerosis by oral administration of autoantigens](#)
- 5858980- [Peptide fragments of myelin basic protein](#)
- 5858968- [Method of treating or preventing type 1 diabetes by oral administration of insulin](#)
- 5858364- [Pharmaceutical dosage form for treatment of multiple sclerosis](#)
- 5856446- [Method of treating rheumatoid arthritis with low dose type II collagen](#)
- 5849298- [Treatment of multiple sclerosis by oral administration of bovine myelin](#)
- 5399347- [Method of treating rheumatoid arthritis with type II collagen](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

